{"id":31046,"date":"2024-08-09T18:04:42","date_gmt":"2024-08-09T16:04:42","guid":{"rendered":"https:\/\/imagineformargo.org\/?p=31046"},"modified":"2024-08-09T18:04:42","modified_gmt":"2024-08-09T16:04:42","slug":"sample-collection-to-establish-a-biological-and-genomic-research-network-on-osteosarcomas-in-france","status":"publish","type":"post","link":"https:\/\/imagineformargo.org\/en\/sample-collection-to-establish-a-biological-and-genomic-research-network-on-osteosarcomas-in-france\/","title":{"rendered":"Sample Collection to Establish a Biological and Genomic Research Network on Osteosarcomas in France"},"content":{"rendered":"

\"ost\u00e9osarcomes\"<\/h3>\n

Osteosarcomas in Children<\/h2>\n

Osteosarcoma is the most common malignant bone tumor or bone cancer (tumors originating in the bone) in adolescents and young adults. Osteosarcoma affects about 100 to 150 new patients per year in France, occurring in young people aged 10 to 25 years and affects boys more (1 girl affected for every 1.4 boys).<\/p>\n

Localized osteosarcomas are confined to the bone, the site of the original tumor development (mainly the femur, around the knee, tibia). In 10 to 20% of cases, metastases are present at diagnosis. These metastases are located in 85 to 90% of cases in the lungs, and others later occur in another bone.<\/p>\n

For more information on osteosarcomas and our projects to better treat this disease: link to osteosarcoma article.<\/p>\n

About the Project<\/h2>\n

Osteosarcoma (OTS) has a cure rate of 70%. However, new treatments are still needed for patients who are refractory to chemotherapy or in relapse.<\/p>\n

Project Objective:<\/strong> Define and characterize sub-classes of OTS at diagnosis with different genetic and biological profiles, taking into account the tumor cell and the bone and immune microenvironment.<\/p>\n

Project Description:<\/strong> This project has made it possible to fully exploit the significant genetic and biological data generated from the collection of tumor, blood, and urine samples prospectively collected during the OS2006 protocol. Each biological (bone remodeling, anti-tumor immunity) or genetic aspect was analyzed with clinical and evolutionary characteristics to answer specific questions. The clinical, biological, and genomic data from the various research teams involved in the protocol were combined into a database to be analyzed integratively to determine subgroups of OTS from diagnosis. This database allows other research teams to evaluate the clinical relevance of their preclinical data.<\/p>\n

The goal of this project is to propose new targeted treatment options to patients (depending on the OTS sub-class) and to create a database usable by all researchers working on different aspects of OTS.<\/p>\n

Project Follow-Up:<\/strong><\/h2>\n